PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2006New England Journal of Medicine5,128 citationsOpen Access

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

View Full Paper
JBJames A. BonnerPHPaul M. HarariJGJ. Giralt

Key Points

  • The aim is to evaluate the effectiveness of high-dose radiotherapy combined with cetuximab in treating locoregionally advanced head and neck cancer.
  • Concomitant high-dose radiotherapy was administered with cetuximab.
  • The study design includes a randomized trial (ClinicalTrials.gov NCT00004227).
  • Improved locoregional control observed with the combination treatment.
  • Reduced mortality rate without increasing common toxic effects associated with radiotherapy.

Abstract

Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bonner et al. (2006) studied this question.

synapsesocial.com/papers/69dc733034612599f33591bdhttps://doi.org/10.1056/nejmoa053422
Ask AI
Helpful
Bookmark
Share
View Full Paper